Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 BNCT with Borofalan (10B) (SPM-011) and CICS-1 in Malignant Melanoma and Angiosarcoma
jRCT1080224974Phase 1Completed
- Sponsor
- Cancer Intelligence Care Systems
- Start
- Dec 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of borofalan in melanoma and angiosarcoma, sponsored by Cancer Intelligence Care Systems. Started Dec 2019; status: completed.
02
Drugs
borofalan
03
Conditions
melanomaangiosarcoma
Beyond the preview
Go deeper on jRCT1080224974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224974.